PhotoCure/Galderma Actinic Keratosis Phototherapy Clears FDA
Executive Summary
PhotoCure/Galderma expect to launch their actinic keratosis phototherapy in "several weeks" following the approval of an alternate tradename
You may also be interested in...
PhotoCure Basal Cell Carcinoma Phototherapy Has “Niche” Market Potential
PhotoCure's methyl aminolevulinate could be approved as part of a "niche" basal cell carcinoma phototherapy regimen for patients who are intolerant to other treatments, an FDA advisory committee said in voting against a broader indication
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials